The latest breakthrough in type 1 diabetes.

Today I will share with you the latest breakthrough in knowledge about type 1 diabetes. If it happens to solve the problem you are currently facing, don't forget to follow this website. Let's begin now! My daughter has type 1 diabetes at such a young age. I really want to take her away from this world because it is so torturous...

Hello, questioner. Type 1 diabetes is mostly genetic, so it is normal for the disease to manifest even though the child is very young. I hope you stay strong. Since the child has been born, you must live on bravely and grow up to become an adult. From now on, comprehensive treatment and adjustment are needed. Firstly, insulin injections are essential to control and stabilize blood sugar, which is the most crucial aspect. Secondly, controlling diet and exercising are crucial to prevent the disease from worsening. Thirdly, a reasonable nutrition plan for the child should be developed because although many foods are beneficial for a child's development, they are not favorable for diabetes control. Therefore, this situation is like walking on a tightrope, steadily adjusting to ensure the child's nutrition while being able to control blood sugar. Sometimes, there may be a need to temporarily relax strict blood sugar control.

I believe that with the rapid development of science, there may be a revolutionary breakthrough in the study of chromosomes one day, and type 1 diabetes may become reversible. Recent Research on Stem Cell Therapy for Diabetes Scientists have made a major breakthrough in treating diabetes using stem cell technology.

-------------------------------------------------------------------------------- Keywords: stem cells, diabetes, insulin According to a report from Guangzhou Daily on the 11th, a recent medical achievement has brought good news to diabetes patients. The UK's The Times reported on the front page that there has been a major breakthrough in treating diabetes using stem cell technology. Clinical trials have shown that diabetes patients treated with stem cells can produce insulin in their bodies, allowing them to stop injecting artificial insulin.

This latest research represents a breakthrough in the treatment of diabetes. In the clinical trial, 15 young people who were recently diagnosed with type 1 diabetes were injected with autologous stem cells. The results of the trial showed that these insulin-dependent diabetes patients no longer relied on artificial insulin injections after receiving autologous stem cell treatment. The medical records of all the volunteers involved in the trial were published in the Journal of the American Medical Association on the 12th. Over the course of more than three years of receiving autologous stem cell transplantation instead of traditional treatment, the patients no longer needed daily insulin injections. This is the first clinical evidence supporting the use of stem cell therapy for diabetes.

Promising Results from Clinical Trials This new research was jointly conducted by scientists from Brazil and the United States. They were amazed to find that one volunteer, over a period of three years, had not injected any artificial insulin after solely relying on human stem cell transplantation. Professor Júlio Voltarelli from the University of São Paulo, the leader of the research team, stated, "These results are truly encouraging."

In his article, Professor Voltarelli wrote, "The trial results show that more than 93% of patients treated with stem cells for type 1 diabetes can achieve independence from artificial insulin at different time intervals. The treatment is minimally toxic, with zero mortality rate." The research team believes that if they intervene in the treatment of diabetes early enough, they have full confidence in completely curing the disease. The research team recruited type 1 diabetes patients aged between 14 and 31 in Brazil, all of whom were newly diagnosed within six weeks.

After extracting stem cells from the patients' blood, the researchers used a gentle chemical treatment to eliminate white blood cells that destroy the pancreas. Then, the stem cells were injected into the patients' bodies to help them rebuild their immune systems. Richard Burt from Northwestern University Feinberg School of Medicine, who participated in the trial, stated that 14 out of the 15 volunteers were able to stop relying on insulin after a certain period of treatment. Among them, 11 experienced immediate effects and no longer needed artificial insulin like before. He also stated, "Two volunteers still required insulin injections within the initial 12 to 20 months, but eventually we helped them overcome the burden of daily injections."

This treatment method, called autologous hematopoietic stem cell transplantation, has previously shown effectiveness in treating autoimmune diseases such as rheumatoid arthritis, lupus, and Crohn's disease. Previous studies have shown that stem cell technology has tremendous potential for treating many complex diseases such as Alzheimer's, Parkinson's, and motor neuron diseases.

Currently, this new method for treating diabetes still needs further verification, including its treatment principles, safety, and effectiveness, among other factors. Diabetes and Insulin Diabetes is a chronic disease caused by a lack of natural insulin secretion in the body, either congenital or due to dysfunction of insulin production. This dysfunction leads to increased glucose levels in the blood, posing a threat to many systems in the body, especially the vascular and nervous systems.

There are two main types of diabetes, with type 1 diabetes previously referred to as insulin-dependent diabetes. In this type of diabetes, the pancreas cannot produce the vital insulin, and it occurs mostly in children and adolescents, but there is an increasing trend among adults. Patients with type 1 diabetes have hormone production impairments due to immune system disorders, so they must control their blood sugar levels by injecting insulin. Typically, patients need to inject insulin at least four times a day. In addition to type 1 diabetes, there is also type 2 diabetes.

What is the best treatment for type 1 diabetes? For type 1 diabetes patients, due to the damage to their own pancreatic beta cells, insulin secretion is absolutely insufficient, so insulin treatment is needed at the onset of the disease, and lifelong insulin replacement therapy is required to maintain life and daily activities. It accounts for about 5% of the total number of diabetes patients. For type 2 diabetes patients, if blood sugar levels have not reached the control target after lifestyle changes and combined oral hypoglycemic medication, combination therapy with oral medication and insulin can be started. When HbA1c remains greater than 7.0% after treatment with multiple oral medications in high doses, starting insulin treatment can be considered. Thin diabetes patients who have difficulty distinguishing between newly developed and type 1 diabetes. In the course of diabetes mellitus (including newly diagnosed type 2 diabetes patients), early insulin treatment should be used when there is unexplained weight loss. For newly diagnosed type 2 diabetes patients with high blood sugar, oral medication is difficult to achieve satisfactory control. Rapid relief of hyperglycemic toxicity can partially reduce insulin resistance and reverse beta cell function. Therefore, insulin intensive therapy can be used for newly diagnosed type 2 diabetes with significantly high blood sugar. Insulin therapy should also be used in some special circumstances: perioperative period; temporary use of insulin during severe acute complications or stress situations, such as diabetic ketoacidosis, hyperosmolar hyperglycemic state, lactic acidosis, infection, etc.; severe chronic complications, such as diabetic foot, severe diabetic nephropathy, etc.; concomitant with some severe diseases, such as coronary heart disease, cerebrovascular disease, hematologic disease, liver disease, etc.; gestational diabetes and pregnant women with diabetes, during pregnancy, before and after delivery, and during lactation, insulin therapy is required if blood sugar cannot achieve the target value with diet control alone, and oral hypoglycemic drugs are contraindicated. Secondary diabetes and specific diabetes patients.

Preparations Insulin can be divided into animal insulin, human insulin, and insulin analogues based on their sources and chemical structures. Human insulin includes the Novolin series, while insulin analogues include Novorapid, Novorapid 30, and Novomix. Based on their duration of action, insulin can be classified into rapid-acting insulin analogues, short-acting insulin, intermediate-acting insulin, long-acting insulin (including long-acting insulin analogues), and premixed insulin (including premixed insulin analogues). Common rapid-acting insulin analogues include Novorapid, while common long-acting insulin analogues include Novomix. Clinical trials have shown that insulin analogues are superior to human insulin in simulating physiological insulin secretion and reducing the risk of hypoglycemia.

Insulin is classified according to its duration of action: 1. Ultra-short-acting: starts working 15 minutes after injection, with a peak concentration of 1-2 hours. 2. Short-acting (rapid-acting): starts working 30 minutes after injection, with a peak concentration of 2-4 hours and lasting 5-8 hours.

3. Long-acting (recombinant human insulin zinc): starts working 4-6 hours after injection, with a peak concentration of 4-20 hours and lasting 24-36 hours. 5. Premix: It refers to the pre-mixture of short-acting and intermediate-acting insulin, which can be injected once and takes effect quickly (within 30 minutes) with a duration of up to 16-20 hours.

Commonly seen in the market are two types of premix: 30% short-acting and 70% intermediate-acting, and equal proportions of short-acting and intermediate-acting premix. It can be used in conjunction with propolis for diabetes. The role of propolis in diabetics mainly lies in lowering blood sugar. Its mechanism is to restore a portion of pancreatic function, repair damaged pancreatic islet cells, and improve their functionality through its own anti-inflammatory, immune, and antioxidant properties. Propolis and some substances contained in it have significant significance in delaying sugar absorption and delaying or reducing postprandial blood sugar elevation. Propolis has a relatively wide range of clinical applications. The difficulty in treatment lies in the relatively low purity of propolis itself, so it should be cautiously and reasonably used in clinical practice. In addition to controlling blood sugar, propolis also has a series of beneficial effects on the human body, such as lowering blood lipids, improving blood circulation, and protecting the liver.

If you want to learn more information about this, remember to bookmark and follow this website.